CommercialCoverageMedium impact
Bone-Anchored Hearing Aids (CPB 0403, reviewed 2026-07-22)
Aetna·Audiology, ENT (Ear, Nose & Throat)·Medical Policy
Effective date
Jul 22, 2026
We identified it
Aug 14, 2026
Summary
Aetna updated its Bone-Anchored Hearing Aids (BAHA) medical policy (CPB 0403) effective July 22, 2026, establishing specific audiologic criteria for coverage based on device type and bone conduction thresholds, and clarifying that replacements are medically necessary only when devices malfunction, cannot be repaired, or when member condition changes. The policy also specifies that upgrades for convenience or aesthetics are not covered, and designates certain devices and indications as experimental/investigational.
Action Required
By July 22, 2026: Billing team must update authorization protocols to apply device-specific bone conduction thresholds (45 dB HL, 55 dB HL, or 65 dB HL depending on BAHA model) before approving implantation claims. Implement rejection logic in billing system to deny replacement/upgrade requests when current device remains functional or when request is for aesthetics/convenience only. Require providers to document in authorization requests: (1) which BAHA device model is being implanted/replaced, (2) the member's current bone conduction thresholds, (3) reason for replacement (malfunction, inability to repair, or medical condition change), and (4) that the upgrade provides clinically significant benefit. Deny claims for bilateral implants unless bone conduction symmetry criteria are met (10 dB average difference between ears or <15 dB at individual frequencies). Deny all claims for intra-oral bone conduction devices (e.g., SoundBite), bilateral pure sensorineural hearing loss, and osteogenesis imperfecta cases not meeting medical necessity criteria as these remain investigational. Update encounter forms and prior authorization templates with these specific requirements. Failure to apply device-specific thresholds and medical necessity documentation will result in claim denials.